Grouped based on clinic pathology and independent prognostic factors, we observed T-stage (T3&T4), N-stage (N1&N2), pathology stage (T3&T4), residual tumor(R1&R2), lymphatic invasion, BMI (< 25) subgroups with high expression of GRID2IP had worse prognosis. The gene discussed is GRID2IP; the disease is neoplasm.